0000899243-18-015794.txt : 20180608
0000899243-18-015794.hdr.sgml : 20180608
20180608173245
ACCESSION NUMBER: 0000899243-18-015794
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180606
FILED AS OF DATE: 20180608
DATE AS OF CHANGE: 20180608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hooks Corwin Dale
CENTRAL INDEX KEY: 0001665347
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 18890509
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 5500 FLATIRON PARKWAY
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-06
0
0001466301
Clovis Oncology, Inc.
CLVS
0001665347
Hooks Corwin Dale
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
2018-06-06
4
M
0
468
A
4919
D
Common Stock
2018-06-06
4
F
0
235
47.70
D
4684
D
Restricted Stock Units
2018-06-06
4
M
0
468
0.00
D
Common Stock
468
5157
D
Each restricted stock unit represents the right to receive one share of Common Stock.
The reporting person filed a Form 4 on June 1, 2018, reporting the conversion of 869 Restricted Stock Units into shares of Common Stock. The amount of securities beneficially owned following this transaction contained a clerical error, and should have been 4,895. The amount of securities beneficially owned after taking into account the second transaction reported on June 1, 2018 remains correct.
On March 27, 2017, the reporting person was granted 7,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Senior Vice President and Chief Commercial Officer
/s/ Corwin Dale Hooks
2018-06-08